October 28, 2016
Young adults with Prader-Willi syndrome who continued previous growth hormone therapy for 1 year after attaining adult height saw no adverse effects on metabolic parameters, according to findings from a randomized crossover study.
“In our cohort of patients who were GH-treated during childhood for many years, none had [metabolic syndrome] at attainment of [adult height] and none developed [metabolic syndrome] during GH therapy after [adult height], while one developed [metabolic syndrome] during placebo treatment,” Renske J. Kuppens, MD, of Erasmus University Medical Center in the Netherlands, and colleagues wrote. “Elaborating on this, it might be that the role of body composition, and subsequently GH treatment, is even larger. Continuation of GH prevents deterioration of body composition and, thus, favorably affects metabolic health.”